8-K: ResMed Reports Strong Q2 FY26 Growth, Boosts Dividend

ResMed Inc. announced robust second-quarter fiscal year 2026 results, with revenue up 11% and non-GAAP diluted EPS increasing by 16%, alongside a declared quarterly cash dividend of $0.60 per share.

Summary

• Revenue for the quarter ended December 31, 2025, increased by 11% to $1.42 billion, or 9% on a constant currency basis, compared to the prior year.
• Non-GAAP gross margin expanded by 310 basis points to 62.3%, driven by manufacturing and logistics efficiencies and component cost improvements.
• Non-GAAP income from operations grew by 19%, and non-GAAP diluted earnings per share increased by 16% to $2.81.
• Operating cash flow for the quarter was $340 million.
• The board of directors declared a quarterly cash dividend of US $0.60 per share, payable on March 19, 2026, to shareholders of record on February 12, 2026.
• ResMed repurchased 704,000 shares for $175 million during the quarter as part of its capital management strategy.
• The company received FDA clearance for 'Smart Comfort,' an AI-enabled digital medical device designed to personalize CPAP comfort settings and improve patient adherence.
• New research published in SLEEP demonstrated that each additional hour of PAP use in OSA patients was linked to a 4.1-6.2% reduction in healthcare utilization over 12-24 months.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive report, driven by strong double-digit revenue and EPS growth, significant margin expansion, and strategic advancements in digital health and product innovation, all supported by a healthy operating cash flow and shareholder returns.

Positives

• Revenue increased by 11% (9% constant currency) to $1.42 billion, indicating strong market demand.
• Gross margin improved significantly by 320 basis points to 61.8%, reflecting enhanced operational efficiencies.
• Non-GAAP diluted earnings per share grew by 16% to $2.81, demonstrating strong profitability.
• Income from operations increased by 18%, with non-GAAP income from operations up 19%.
• Operating cash flow was a healthy $340 million for the quarter.
• The company declared a quarterly cash dividend of $0.60 per share, signaling confidence in future performance and returning value to shareholders.
• FDA clearance for 'Smart Comfort' highlights innovation and potential for improved patient outcomes and adherence.
• Positive research findings on PAP use and healthcare utilization reinforce the value proposition of ResMed's core products.

Negatives

• Selling, general, and administrative (SG&A) expenses increased by 12% on a constant currency basis, primarily due to the VirtuOx acquisition, employee costs, and marketing/technology investments.
• SG&A expenses as a percentage of revenue increased to 19.6% from 18.8% in the prior year period.
• Restructuring-related charges of $6 million were recorded following workforce planning activities, indicating some organizational adjustments.

Risks

• Projections of future revenue or earnings, expenses, new product development, new product launches, and new markets are subject to risks and uncertainties.
• The integration of acquisitions, supply chain disruptions, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions could materially differ from projections.
• The company does not undertake to update its forward-looking statements, meaning investors rely on current information without guaranteed future updates on these projections.

Future Outlook

Management plans to continue investing in innovation to scale digital health capabilities and expand global access to life-saving care, aiming for sustainable, profitable growth in the second half of fiscal year 2026. The company's long-term growth opportunities, connected-care ecosystem, and continued leadership in digital sleep and respiratory health were highlighted at the J.P. Morgan Healthcare Conference.

Management Comments

• "Our second quarter results demonstrate the strength and resilience of our global business as we continue advancing our mission to help people sleep better, breathe better, and live longer and healthier lives in the comfort of their own home."
• "Year-over-year, we delivered 11% headline revenue growth, 310 basis points of non-GAAP gross margin expansion, and continued operating excellence, resulting in another quarter of mid-teens non-GAAP EPS growth."
• "These results reflect strong ongoing demand for our market-leading sleep and respiratory care devices, as well as the growing impact of our digital health ecosystem that spans more than 140 countries."
• "As we move into the second half of fiscal year 2026, we will continue to invest in innovation to scale our digital health capabilities and expand global access to life-saving care, while delivering sustainable, profitable growth."

Industry Context

StockSavvy.ai notes that ResMed's strong performance, particularly in digital health and connected care, aligns with broader industry trends emphasizing remote patient monitoring, personalized medicine, and home-based healthcare solutions. The FDA clearance for an AI-enabled device positions ResMed favorably in the evolving landscape of smart medical devices, while the positive research on PAP use reinforces the clinical and economic value of its core offerings in a growing market for sleep and respiratory disorders.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Will benefit from the increased quarterly cash dividend of $0.60 per share and ongoing share repurchase program, indicating strong returns and confidence in future performance.
• Customers/Patients: Will benefit from continued innovation, such as the FDA-cleared 'Smart Comfort' device, designed to improve CPAP adherence and personalized care, leading to better health outcomes.
• Employees: Some employees were impacted by restructuring-related charges totaling $6 million following company-wide workforce planning activities, which included severance and termination benefits.
• Investors: Provided with strong financial results, including significant revenue and EPS growth, and positive operational highlights, which may enhance investor confidence.

Next Steps

• Continue to invest in innovation to scale digital health capabilities.
• Expand global access to life-saving care.
• Deliver sustainable, profitable growth in the second half of fiscal year 2026.
• Payment of quarterly cash dividend on March 19, 2026.

Key Dates

Recommendation

The filing demonstrates exceptional financial performance with double-digit growth in revenue, gross margin, and EPS, indicating strong operational efficiency and market demand. Strategic initiatives like FDA clearance for AI-enabled devices and positive research findings reinforce the company's competitive advantage and future growth potential. The dividend increase and share repurchases further signal management's confidence and commitment to shareholder value. These factors collectively suggest a strong investment opportunity.

Keywords

ResMed, RMD, Earnings, Q2 2026, Financial Results, Sleep Apnea, Respiratory Care, CPAP, Digital Health, Dividend, FDA Clearance, Gross Margin, EPS, Healthcare Technology